BioXcel Therapeutics (BTAI) Gross Margin (2022 - 2026)

BioXcel Therapeutics' Gross Margin history runs 5 years deep, the most recent figure standing at 37.38% for Q1 2026.

• On a quarterly basis, Gross Margin fell 12905.0% year-over-year to 37.38% in Q1 2026; TTM through Mar 2026 was 36.32%, a 4853.0% increase from a year earlier, with the FY2025 full-year figure at 74.45%, up 6903.0% from the prior year.
• Gross Margin retreated to 37.38% in Q1 2026 per BTAI's latest filing, from 87.5% in the prior quarter.
• Across five years, Gross Margin topped out at 96.22% in Q4 2022 and bottomed at 446.73% in Q3 2024.
• The 5-year median for Gross Margin is 87.5% (2025), against an average of 5.74%.
• Across the five-year window, Gross Margin tumbled 39658 bps in 2024 and surged 53550 bps in 2025, its largest moves.
• Year by year, Gross Margin stood at 96.22% in 2022, then tumbled by 193 bps to 89.89% in 2023, then sank by 42 bps to 127.32% in 2024, then soared by 169 bps to 87.5% in 2025, then slumped by 143 bps to 37.38% in 2026.
• Per Business Quant, the three latest BTAI Gross Margin figures stand at 37.38% (Q1 2026), 87.5% (Q4 2025), and 88.78% (Q3 2025).